Organogenesis Trial Shows PuraPly AM Improves Wound Healing Outcomes Over Standard Care

Organogenesis announced that its randomized controlled trial evaluating PuraPly® AM, a wound management product, has successfully met its primary endpoint. The study aimed to assess the effectiveness of PuraPly® AM in managing complex wounds compared to standard care treatments. According to the company, the trial results demonstrated statistically significant improvements in wound healing outcomes for patients treated with PuraPly® AM.

The clinical trial involved a diverse patient population and compared the use of PuraPly® AM against conventional wound care methods. Researchers measured key indicators such as wound closure rates and time to healing. The findings revealed that patients receiving PuraPly® AM experienced faster and more consistent healing progress than those undergoing standard treatment protocols. Organogenesis stated that these results underscore the potential benefits of incorporating PuraPly® AM into broader wound care practices. Further details about the study design or additional data were not disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 6, 2026

Author

GOAI